arBtrage CAPITALIZING MARKETS — checking… Sign in Sign up
Calendar /

Maravai LifeSciences Holdings, Inc.

MRVI Health Care Biotechnology: Pharmaceutical Preparations
$7.32
Today
as of Sep 4, 16:51 ET
Last 30 days +6.71% Jul 28 → Sep 04
$5.41 $6.38 $7.34 $8.30 $9.27 Jul 28 Aug 05 Aug 12 Aug 20 Aug 27 Sep 04
Open
$7.25
High
$7.43
Low
$7.17
Volume
$2M
Avg Vol
$2M
Mkt Cap
$2.2B
P/E (TTM)
—
Beta
—
52w High
$9.42
52w Low
$2.42
Div Yield
—
Shares Out
—

Recent Press Releases & News last 60 days · 8 items

Aug 14 · 00:16 Motley Fool
Maravai (MRVI) Q2 2026 Earnings Call Transcript
Aug 7 · 12:58 MT Newswires
Deutsche Bank Adjusts Maravai Lifesciences PT to $8 From $6, Maintains Buy Rating
Aug 7 · 12:30 Moby
Maravai LifeSciences Holdings, Inc. Q2 2026 Earnings Call Summary
▸ Show all 8 press releases & news Free account →

Overview

52-week range
$2.42
$9.42
70% of range
Avg surprise (last 3)
-8.7%
Avg reaction (last 2)
+3.5%
50% positive
Latest IV / EM
101%
EM ±15.7% · $8 · Sep 18

Earnings trends

EPS — actual vs estimate Actual Estimate
$-0.68$-0.52$-0.36$-0.19$-0.03 Actual $-0.05Actual $-0.05Actual $-0.09Actual $-0.07Actual $-0.68Actual $-0.15Est $-0.10Actual $-0.12Est $-0.09Actual $-0.18Actual $-0.03Est $-0.07Actual $-0.08 MarJunSepMarJunSepMar/2025Jun/2025SepMar/2026Jun
Revenue vs Net Income Revenue Net income
$-97M$-55M$-12M$30M$72M Sep 24Mar 25Jun 25Sep 25Mar 26Jun 26

Earnings history

DatePeriodActual EPSEstSurpriseYoY %ΔDay reactSource
Tue Jun 30, 2026Jun 2026 $-0.08 — — — — financials
Thu May 7, 2026Mar/2026 $-0.03 $-0.07 +57.1% +80.0% 0.0% earnings
Tue Sep 30, 2025Sep 2025 $-0.18 — — — — financials
Mon Aug 11, 2025Jun/2025 $-0.12 $-0.09 -33.3% — — earnings
Mon May 12, 2025Mar/2025 $-0.15 $-0.10 -50.0% — +7.1% earnings
Mon Sep 30, 2024Sep 2024 $-0.68 — — — — financials
Sun Jun 30, 2024Jun 2024 $-0.07 — — — — financials
Sun Mar 31, 2024Mar 2024 $-0.09 — — — — financials
Sat Sep 30, 2023Sep 2023 $-0.05 — — — — financials
Fri Jun 30, 2023Jun 2023 $-0.05 — — — — financials
Fri Mar 31, 2023Mar 2023 — — — — — financials

Financials

Income statement (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue$51M$66M—$42M$47M$47M—$69M
Cost of revenue$31M$32M—$36M$40M$39M—$37M
Gross profit$21M$34M—$6M$8M$8M—$32M
Operating income$-15M$-2M—$-41M$-66M$-49M—$-166M
Net income$-12M$-4M—$-26M$-40M$-30M—$-97M
EPS (diluted)$-0.08$-0.02—$-0.18$-0.27$-0.21—$-0.68

Balance sheet (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Cash & equivalents$70M$166M$217M$244M$270M$285M$322M—
Inventory$41M$40M$40M$45M$47M$50M$50M—
Total current assets$156M$252M$296M$326M$360M$376M$429M—
Total assets$604M$713M$771M$849M$897M$960M$1.01B—
Long-term debt$146M$236M$286M$287M$288M$289M$290M—
Total liabilities$248M$344M$398M$417M$429M$429M$431M—
Total equity$205M$369M$212M$245M$468M$530M$325M$613M

Implied volatility — last 90 days

69%179%290%400%511% Jun 07 — IV 79% · EM ±11.0%Jun 08 — IV 90% · EM ±11.9%Jun 09 — IV 70% · EM ±8.8%Jun 10 — IV 125% · EM ±14.8%Jun 11 — IV 217% · EM ±24.0%Jun 12 — IV 226% · EM ±23.1%Jun 15 — IV 98% · EM ±7.1%Jun 16 — IV 220% · EM ±13.0%Jun 17 — IV 206% · EM ±8.6%Jun 19 — IV 70% · EM ±15.4%Jun 22 — IV 123% · EM ±25.7%Jun 23 — IV 105% · EM ±21.4%Jun 24 — IV 192% · EM ±38.5%Jun 25 — IV 206% · EM ±40.3%Jun 26 — IV 217% · EM ±41.6%Jun 29 — IV 236% · EM ±41.9%Jun 30 — IV 205% · EM ±35.3%Jul 01 — IV 243% · EM ±40.6%Jul 02 — IV 205% · EM ±33.1%Jul 03 — IV 212% · EM ±33.1%Jul 06 — IV 247% · EM ±34.2%Jul 07 — IV 256% · EM ±33.8%Jul 08 — IV 208% · EM ±26.0%Jul 09 — IV 234% · EM ±27.6%Jul 10 — IV 312% · EM ±34.5%Jul 13 — IV 508% · EM ±42.5%Jul 14 — IV 403% · EM ±29.2%Jul 15 — IV 385% · EM ±22.8%Jul 16 — IV 350% · EM ±14.6%Jul 20 — IV 85% · EM ±20.0%Jul 21 — IV 117% · EM ±27.1%Jul 22 — IV 105% · EM ±23.9%Jul 23 — IV 95% · EM ±21.3%Jul 24 — IV 114% · EM ±25.1%Jul 27 — IV 186% · EM ±38.9%Jul 28 — IV 132% · EM ±27.0%Jul 29 — IV 205% · EM ±41.0%Jul 30 — IV 140% · EM ±27.4%Jul 31 — IV 215% · EM ±41.1%Aug 03 — IV 255% · EM ±45.2%Aug 04 — IV 262% · EM ±45.1%Aug 05 — IV 262% · EM ±43.8%Aug 06 — IV 298% · EM ±48.2%Aug 07 — IV 247% · EM ±38.5%Aug 10 — IV 297% · EM ±41.2%Aug 11 — IV 261% · EM ±34.4%Aug 12 — IV 242% · EM ±30.3%Aug 13 — IV 249% · EM ±29.4%Aug 14 — IV 238% · EM ±26.3%Aug 17 — IV 309% · EM ±25.8%Aug 18 — IV 361% · EM ±26.1%Aug 19 — IV 245% · EM ±14.5%Aug 20 — IV 511% · EM ±21.3%Aug 24 — IV 99% · EM ±20.8%Aug 25 — IV 113% · EM ±23.1%Aug 26 — IV 118% · EM ±23.6%Aug 27 — IV 96% · EM ±18.8%Aug 28 — IV 101% · EM ±19.3%Aug 31 — IV 93% · EM ±16.6%Sep 01 — IV 91% · EM ±15.7%Sep 02 — IV 93% · EM ±15.6%Sep 03 — IV 103% · EM ±16.6%Sep 04 — IV 101% · EM ±15.7%

Sector peers

LLY
Eli Lilly and Company
$1.1T $1,148.00-0.1%
JNJ
Johnson & Johnson
$671.0B $275.71+0.2%
ABBV
AbbVie Inc.
$430.9B $256.50+0.1%
MRK
Merck & Company, Inc.
$317.1B $150.33+0.0%
PM
Philip Morris International Inc
$299.3B $182.53+0.0%
NVS
Novartis AG
$297.9B $155.11-3.0%
View on Nasdaq ↗
🔒 Preview mode. Create a free account to unlock the full earnings calendar, all panels, heatmaps, options flow, and screener.
Sign up free → Sign in